Effect of Chronic Central Administration of Glucagon‐Like Peptide‐1 (7–36) Amide on Food Consumption and Body Weight in Normal and Obese Rats
Open Access
- 1 March 1998
- journal article
- research article
- Published by Wiley in Obesity Research
- Vol. 6 (2) , 147-156
- https://doi.org/10.1002/j.1550-8528.1998.tb00329.x
Abstract
Glucagon‐like peptide (7–36) amide (GLP‐1) acutely inhibits food and water consumption in rats after intrace‐rebroventricular (icv) administration. To assess the potential for desensitization of these effects, we investigated the effects of chronic icv administration of GLP‐1 on food consumption and body weight in Sprague‐Dawley (SD) rats and Zucker (fa/fa) obese rats. In vitro functional densensitization of the GLP‐1 receptor was not observed after overnight exposure of Rin m5F insulinoma cells to GLP‐1 at concentrations up to 10 nM. Administration of GLP‐1 to SD rats (30 ug icv twice a day for 6 days) resulted in significant reductions in 24‐hour food consumption each day (25 ±1%). Continuous icv infusion of GLP‐1 for 7 and 14 days significantly inhibited cumulative food consumption and reduced body weight in SD rats. In the genetically obese Zucker rat, chronic dosing with GLP‐1 (30 ug icv) once a day for 6 days caused significant reductions in food consumption each day and a reduction in body weight. These results indicate that the GLP‐1 pathways in the central nervous system controlling food consumption do not desensitize after chronic exposure to GLP‐1 and suggest that agonists of the central GLP‐1 receptor may be effective agents for the treatment of obesity.Keywords
This publication has 18 references indexed in Scilit:
- Glucagon-like peptide-1 and satietyNature, 1997
- Colocalization of Glucagon‐Like Peptide‐1 (GLP‐1) Receptors, Glucose Transporter GLUT‐2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP‐1 Receptor Agonists as an Inhibitory Signal for Food and Water IntakeJournal of Neurochemistry, 1996
- The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM PatientsDiabetes Care, 1996
- Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP- 1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetateMolecular Endocrinology, 1996
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding SitesEuropean Journal of Neuroscience, 1995
- Glucagon-like peptide-1 is a physiological incretin in rat.Journal of Clinical Investigation, 1995
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical studyJournal of Comparative Neurology, 1988
- Cellular localization of proglucagon/glucagon‐like peptide I messenger RNAs in rat brainJournal of Neuroscience Research, 1986